Condition: High Risk Cardiovascular Disease · Hypertension · High Cardiovascular Risk · Sponsor: Alnylam Pharmaceuticals
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
This description comes directly from the study's public registry record.
Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Birmingham, Alabama, United States | Recruiting |
| Clinical Trial Site | Birmingham, Alabama, United States | Recruiting |
| Clinical Trial Site | Fairhope, Alabama, United States | Recruiting |
| Clinical Trial Site | Foley, Alabama, United States | Recruiting |
| Clinical Trial Site | Huntsville, Alabama, United States | Not Yet Recruiting |
| Clinical Trial Site | Huntsville, Alabama, United States | Recruiting |
| Clinical Trial Site | Sheffield, Alabama, United States | Recruiting |
| Clinical Trial Site | Chandler, Arizona, United States | Recruiting |
| Clinical Trial Site | Gilbert, Arizona, United States | Recruiting |
| Clinical Trial Site | Glendale, Arizona, United States | Not Yet Recruiting |
| Clinical Trial Site | Mesa, Arizona, United States | Recruiting |
| Clinical Trial Site | Phoenix, Arizona, United States | Recruiting |
+ 983 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07181109